Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
CNC · NYSE · Healthcare
Fundamental quality
50
out of 100
Centene Corp is going through a tough financial stretch: it hasn't been profitable over the last twelve months. On fundamental quality it scores 50 out of 100, profiling it as a company with demanding fundamentals. Its weakest area is its profitability (net margin -2.5%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Centene is America's largest low-income health insurer: it runs Medicaid plans on behalf of states and sells subsidized Obamacare marketplace coverage. Its end customer is fragile; its payer is the government.
Revenue growth: 11.6%
Net margin: -2.5% · ROE: -22.6%
Net debt/EBITDA: 1.83x · FCF: 4.4%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 111,115 | 1,808 | 4,634 | 5,979 |
| 2021 | 125,982 | 1,347 | 3,295 | 5,720 |
| 2022 | 144,547 | 1,202 | 5,257 | 5,946 |
| 2023 | 153,999 | 2,702 | 7,254 | 636 |
| 2024 | 163,071 | 3,305 | -490 | 4,470 |
| 2025 | 194,777 | -6,674 | 4,321 | -487 |
Between 2020 and 2025, revenue went from $111,115M to $194,777M (+75%) and net income went from $1,808M to -$6,674M (-469%). It has also reduced its net debt over the period.
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Centene Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Centene Corp a good company to invest in?
In terms of business quality, Centene Corp scores 50 out of 100 in our analysis, placing it as a company with demanding fundamentals. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Centene Corp a profitable company?
Over the last twelve months, no: Centene Corp posts a negative net margin (-2.5%).
Does Centene Corp have a lot of debt?
A moderate level: its net debt is 1.83 times its EBITDA.
Is Centene Corp growing?
Its revenue has grown 11.6% annualized in recent years, and without interruption since 2020.
Does Centene Corp generate cash?
Yes. It converts about 4.4% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Oscar Health (OSCR) · Recursion Pharmaceuticals (RXRX) · Eli Lilly (LLY) · UnitedHealth (UNH) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Centene Corp's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.